117 related articles for article (PubMed ID: 37005537)
1.
Shahid I; Shoaib M; Raza RZ; Jahangir M; Abbasi SW; Riasat A; Akbar A; Mehnaz S
Anticancer Agents Med Chem; 2023; 23(12):1388-1396. PubMed ID: 37005537
[TBL] [Abstract][Full Text] [Related]
2. Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis.
Nagalingam A; Arbiser JL; Bonner MY; Saxena NK; Sharma D
Breast Cancer Res; 2012 Feb; 14(1):R35. PubMed ID: 22353783
[TBL] [Abstract][Full Text] [Related]
3. Activation of tumor suppressor LKB1 by honokiol abrogates cancer stem-like phenotype in breast cancer via inhibition of oncogenic Stat3.
Sengupta S; Nagalingam A; Muniraj N; Bonner MY; Mistriotis P; Afthinos A; Kuppusamy P; Lanoue D; Cho S; Korangath P; Shriver M; Begum A; Merino VF; Huang CY; Arbiser JL; Matsui W; Győrffy B; Konstantopoulos K; Sukumar S; Marignani PA; Saxena NK; Sharma D
Oncogene; 2017 Oct; 36(41):5709-5721. PubMed ID: 28581518
[TBL] [Abstract][Full Text] [Related]
4. Chemical Characterization,
Ansari JA; Ahmad MK; Fatima N; Azad I; Mahdi AA; Satyanarayan GNV; Ahmad N
Anticancer Agents Med Chem; 2022; 22(20):3416-3437. PubMed ID: 35125087
[TBL] [Abstract][Full Text] [Related]
5. Screening the possible anti-cancer constituents of Hibiscus rosa-sinensis flower to address mammalian target of rapamycin: an in silico molecular docking, HYDE scoring, dynamic studies, and pharmacokinetic prediction.
Rasul HO; Aziz BK; Ghafour DD; Kivrak A
Mol Divers; 2023 Oct; 27(5):2273-2296. PubMed ID: 36318405
[TBL] [Abstract][Full Text] [Related]
6. Honokiol activates LKB1-miR-34a axis and antagonizes the oncogenic actions of leptin in breast cancer.
Avtanski DB; Nagalingam A; Bonner MY; Arbiser JL; Saxena NK; Sharma D
Oncotarget; 2015 Oct; 6(30):29947-62. PubMed ID: 26359358
[TBL] [Abstract][Full Text] [Related]
7. In silico molecular docking and dynamic simulation of eugenol compounds against breast cancer.
Rasul HO; Aziz BK; Ghafour DD; Kivrak A
J Mol Model; 2021 Dec; 28(1):17. PubMed ID: 34962586
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, Molecular Docking, Molecular Dynamics Studies, and Biological Evaluation of 4H-Chromone-1,2,3,4-tetrahydropyrimidine-5-carboxylate Derivatives as Potential Antileukemic Agents.
Dolatkhah Z; Javanshir S; Sadr AS; Hosseini J; Sardari S
J Chem Inf Model; 2017 Jun; 57(6):1246-1257. PubMed ID: 28524659
[TBL] [Abstract][Full Text] [Related]
9. Discovery of potential mTOR inhibitors from Cichorium intybus to find new candidate drugs targeting the pathological protein related to the breast cancer: an integrated computational approach.
Rasul HO; Aziz BK; Ghafour DD; Kivrak A
Mol Divers; 2023 Jun; 27(3):1141-1162. PubMed ID: 35737256
[TBL] [Abstract][Full Text] [Related]
10. Honokiol activates the LKB1-AMPK signaling pathway and attenuates the lipid accumulation in hepatocytes.
Seo MS; Kim JH; Kim HJ; Chang KC; Park SW
Toxicol Appl Pharmacol; 2015 Apr; 284(2):113-24. PubMed ID: 25737164
[TBL] [Abstract][Full Text] [Related]
11. LKB1 protein expression in human breast cancer.
Fenton H; Carlile B; Montgomery EA; Carraway H; Herman J; Sahin F; Su GH; Argani P
Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):146-53. PubMed ID: 16785781
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
[TBL] [Abstract][Full Text] [Related]
13. Molecular Dynamics and Biological Evaluation of 2-chloro-7-cyclopentyl- 7H-pyrrolo[2,3-d]pyrimidine Derivatives Against Breast Cancer.
Singaram K; Marimuthu D; Baskaran S; Chinaga SK; Shanmugarajan D; Vadivel T
Comb Chem High Throughput Screen; 2017; 20(8):703-712. PubMed ID: 28738766
[TBL] [Abstract][Full Text] [Related]
14. Insights into the structural dynamics of Liver kinase B1 (LKB1) by the binding of STe20 Related Adapterα (STRADα) and Mouse protein 25α (MO25α) co-activators.
Rungsung I; Ramaswamy A
J Biomol Struct Dyn; 2017 Apr; 35(5):1138-1152. PubMed ID: 27160967
[TBL] [Abstract][Full Text] [Related]
15. An
Malkaje S; Srinivasa MG; Deshpande N S; Navada S; Revanasiddappa Bc
Curr Drug Res Rev; 2023; 15(1):88-100. PubMed ID: 36017854
[TBL] [Abstract][Full Text] [Related]
16. Structure-based virtual screening and molecular docking for the identification of potential multi-targeted inhibitors against breast cancer.
Yousuf Z; Iman K; Iftikhar N; Mirza MU
Breast Cancer (Dove Med Press); 2017; 9():447-459. PubMed ID: 28652811
[TBL] [Abstract][Full Text] [Related]
17. 5-Formylhonokiol exerts anti-angiogenesis activity via inactivating the ERK signaling pathway.
Zhu W; Fu A; Hu J; Wang T; Luo Y; Peng M; Ma Y; Wei Y; Chen L
Exp Mol Med; 2011 Mar; 43(3):146-52. PubMed ID: 21297378
[TBL] [Abstract][Full Text] [Related]
18. In silico assessment of new progesterone receptor inhibitors using molecular dynamics: a new insight into breast cancer treatment.
Zarezade V; Abolghasemi M; Rahim F; Veisi A; Behbahani M
J Mol Model; 2018 Nov; 24(12):337. PubMed ID: 30415281
[TBL] [Abstract][Full Text] [Related]
19. Investigation of the New Inhibitors by Sulfadiazine and Modified Derivatives of α-D-glucopyranoside for White Spot Syndrome Virus Disease of Shrimp by In Silico: Quantum Calculations, Molecular Docking, ADMET and Molecular Dynamics Study.
Kumer A; Chakma U; Rana MM; Chandro A; Akash S; Elseehy MM; Albogami S; El-Shehawi AM
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744817
[TBL] [Abstract][Full Text] [Related]
20. The tumor suppressor gene LKB1 is associated with prognosis in human breast carcinoma.
Shen Z; Wen XF; Lan F; Shen ZZ; Shao ZM
Clin Cancer Res; 2002 Jul; 8(7):2085-90. PubMed ID: 12114407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
